Ardelyx, Inc. (ARDX) Stock Score, Valuation & Financial Research
Ardelyx, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for ARDX
Ardelyx, Inc. currently has a Wall Street Score of 22/100. The stored market price is $3.52. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Ardelyx, Inc. does
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart funct
ARDX financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $3.52
- Market capitalization:
- $869.5M
- Revenue:
- $450.9M
- Net income:
- $-55.7M
- Free cash flow:
- $-44.0M
- Cash:
- $97.2M
- Total debt:
- $256.2M
- EPS:
- -0.23
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 36/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-44.0M, showing cash burn in the current stored period.
- The balance sheet shows $97.2M of cash versus $256.2M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARDX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.